Related references
Note: Only part of the references are listed.BRAF Mutations in Colorectal Cancer Are Associated With Distinct Clinical Characteristics and Worse Prognosis
Matthew F. Kalady et al.
DISEASES OF THE COLON & RECTUM (2012)
Multicenter Randomized Phase II Clinical Trial Comparing Neoadjuvant Oxaliplatin, Capecitabine, and Preoperative Radiotherapy With or Without Cetuximab Followed by Total Mesorectal Excision in Patients With High-Risk Rectal Cancer (EXPERT-C)
Alice Dewdney et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2011)
PREOPERATIVE CHEMORADIATION WITH CETUXIMAB, IRINOTECAN, AND CAPECITABINE IN PATIENTS WITH LOCALLY ADVANCED RESECTABLE RECTAL CANCER: A MULTICENTER PHASE II STUDY
Sun Young Kim et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Capecitabine (Cape) versus 5-fluorouracil (5-FU)-based (neo) adjuvant chemoradiotherapy (CRT) for locally advanced rectal cancer (LARC): Long-term results of a randomized, phase III trial
R. Hofheinz et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A phase II study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer
V. Velenik et al.
EJSO (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a Phase II, Open-Label, Randomized Trial Evaluating the Impact of a Pre-Emptive Skin Treatment Regimen on Skin Toxicities and Quality of Life in Patients With Metastatic Colorectal Cancer
Mario E. Lacouture et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Comparison of Two Neoadjuvant Chemoradiotherapy Regimens for Locally Advanced Rectal Cancer: Results of the Phase III Trial ACCORD 12/0405-Prodige 2
Jean-Pierre Gerard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
James A. Bonner et al.
LANCET ONCOLOGY (2010)
KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Jochen Gaedcke et al.
RADIOTHERAPY AND ONCOLOGY (2010)
Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer
C. Bengala et al.
ANNALS OF ONCOLOGY (2009)
CETUXIMAB IN COMBINATION WITH CAPECITABINE, IRINOTECAN, AND RADIOTHERAPY FOR PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER: RESULTS OF A PHASE II MARGIT TRIAL
Karoline Horisberger et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
NEOADJUVANT TREATMENT WITH SINGLE-AGENT CETUXIMAB FOLLOWED BY 5-FU, CETUXIMAB, AND PELVIC RADIOTHERAPY: A PHASE II STUDY IN LOCALLY ADVANCED RECTAL CANCER
Federica Bertolini et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Molecular Response to Cetuximab and Efficacy of Preoperative Cetuximab-Based Chemoradiation in Rectal Cancer
Annelies Debucquoy et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
Carsten Bokemeyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer
Salvatore Siena et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
A Simplified Tumor Regression Grade Correlates with Survival in Locally Advanced Rectal Carcinoma Treated with Neoadjuvant Chemoradiotherapy
D. Beddy et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer
Claus Roedel et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
K-ras mutations and benefit from cetuximab in advanced colorectal cancer
Christos S. Karapetis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab
Andrea Sartore-Bianchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
Shirin Khambata-Ford et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer
J. -P. Machiels et al.
ANNALS OF ONCOLOGY (2007)
Chemotherapy with preoperative radiotherapy in rectal cancer
Jean-Francois Bosset et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer
JG Guillem et al.
ANNALS OF SURGERY (2005)
Treatment of locally advanced rectal cancer
RA Klaassen et al.
SURGICAL ONCOLOGY-OXFORD (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Preoperative versus postoperative chemoradiotherapy for rectal cancer
R Sauer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The epidermal growth factor receptor mediates radioresistance
K Liang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
Outcome and late functional results after anastomotic leakage following mesorectal excision for rectal cancer
A Nesbakken et al.
BRITISH JOURNAL OF SURGERY (2001)
Risk factors for anastomotic leakage after low anterior resection with total mesorectal excision
WL Law et al.
AMERICAN JOURNAL OF SURGERY (2000)
Share Paper
